Personalized mRNA vaccines show promise as a pancreatic cancer treatment, according to a small, early stage trial published Wednesday. Fewer than 13% of people live more than five years after ...

An experimental approach to treating pancreatic cancer with the messenger RNA (mRNA)-based therapeutic cancer vaccine autogene cevumeran continues to show potential to stimulate an immune response ...

A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage pancreatic cancer patients. Latest U.S.

A new mRNA vaccine could prevent pancreatic cancer from returning — potentially for the long haul. In a small clinical trial, some patients who received the vaccine remained cancer-free for more ...

FRIDAY, Feb. 21, 2025 (HealthDay News) -- Adding a personalized mRNA vaccine to standard treatment could offer new hope for pancreatic cancer patients, a small yet promising study from Memorial ...

A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study co-author Dr. Vinod Balachandran talks about the impact on future cancer care.

A recent study found that mRNA-based vaccines may help to delay the recurrence of pancreatic cancer by generating long-lasting immune responses. The phase 1 trial results, published Feb. 19 in ...

There is new hope in the fight against pancreatic cancer after early trials showed that personalized mRNA vaccines can target and reduce malignant tumors. NBC News medical contributor Dr. Kavita ...

Pancreatic cancer is notoriously difficult to treat, and about 90% of diagnosed patients die from the disease. A team at Memorial Sloan Kettering has been working to improve those outcomes by ...

Vaccines using mRNA are currently being studied for a wide range of diseases, including cancer, cardiovascular disease, autoimmune disorders like Type 1 diabetes and rare diseases like cystic ...

Personalized mRNA vaccines show promise as pancreatic cancer treatment, a phase 1 clinical trial published Wednesday in ...